

# Laurent Greillier

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5175791/publications.pdf>

Version: 2024-02-01

69  
papers

4,262  
citations

218592

26  
h-index

118793

62  
g-index

70  
all docs

70  
docs citations

70  
times ranked

4703  
citing authors

#	ARTICLE	IF	CITATIONS
1	PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients. <i>Clinical Lung Cancer</i> , 2022, 23, e243-e246.	1.1	20
2	Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC network. <i>European Journal of Cancer</i> , 2022, 162, 118-127.	1.3	6
3	Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring <i>HER2</i> Mutations: Results From the IFCT-1703 R2D2 Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 719-728.	0.8	37
4	Functional status in older patients with lung cancer: an observational cohort study. <i>Supportive Care in Cancer</i> , 2022, 30, 3817-3827.	1.0	2
5	Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/French-Language Oncology Group (GOLF). <i>Cancers</i> , 2022, 14, 769.	1.7	9
6	First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. <i>Annals of Oncology</i> , 2022, 33, 488-499.	0.6	99
7	Clinical Impact of High Throughput Sequencing on Liquid Biopsy in Advanced Solid Cancer. <i>Current Oncology</i> , 2022, 29, 1902-1918.	0.9	5
8	Prognostic Value of the B12/CRP Index in Older Systemically Treatable Cancer Patients. <i>Cancers</i> , 2022, 14, 169.	1.7	4
9	Acceptance, efficacy, and safety of COVID-19 vaccination in older patients with cancer. <i>Journal of Geriatric Oncology</i> , 2022, 13, 850-855.	0.5	5
10	Older Patients Treated for Lung and Thoracic Cancers: Unplanned Hospitalizations and Overall Survival. <i>Clinical Lung Cancer</i> , 2021, 22, e405-e414.	1.1	5
11	Early-stage non-small cell lung cancer beyond life expectancy: Still not too old for surgery?. <i>Lung Cancer</i> , 2021, 152, 86-93.	0.9	6
12	Octogenarians treated for thoracic and lung cancers: Impact of comprehensive geriatric assessment. <i>Journal of Geriatric Oncology</i> , 2021, 12, 402-409.	0.5	8
13	First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2021, 397, 375-386.	6.3	638
14	Successful Lung Cryoablation for a Bulky Lung Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2021, 32, 610.	0.2	0
15	Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. <i>Journal of Clinical Oncology</i> , 2021, 39, 1349-1359.	0.8	147
16	Functional status in older patients with cancer. <i>Journal of Geriatric Oncology</i> , 2021, , .	0.5	4
17	Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA). <i>Lung Cancer</i> , 2021, 157, 124-130.	0.9	5
18	The Value of Population Screening in Advancing Personalized Medicine in the Field of Lung Cancer. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 987-996.	0.4	1

#	ARTICLE	IF	CITATIONS
19	First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression $\geq 50\%$ . <i>Future Oncology</i> , 2021, 17, 3007-3016.	1.1	6
20	Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trial. <i>Lung Cancer</i> , 2021, 158, 146-150.	0.9	11
21	A Phase 1&2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1559-1569.	0.5	41
22	Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1547-1558.	0.5	108
23	Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02&15 study). <i>Lung Cancer</i> , 2021, 161, 122-127.	0.9	2
24	Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data. <i>Cancers</i> , 2021, 13, 6210.	1.7	19
25	Prise en charge diagnostique et th&eacute;rapeutique du m&eacute;soth&eacute;liome pleural malin en 2020. <i>Revue Des Maladies Respiratoires Actualites</i> , 2020, 12, 2S141-2S149.	0.0	0
26	Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab. <i>Journal of Clinical Medicine</i> , 2020, 9, 3861.	1.0	23
27	Immune Oncology Biomarkers in Lung Cancer: an Overview. <i>Current Oncology Reports</i> , 2020, 22, 107.	1.8	8
28	High Serum Vitamin B12 Levels Associated with C&eacute;Reactive Protein in Older Patients with Cancer. <i>Oncologist</i> , 2020, 25, e1980-e1989.	1.9	5
29	Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1224-1233.	5.1	80
30	LBA53 Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients (pts) treated with PD1/L1 immune checkpoint inhibitors (ICIs): A first analysis of the PIONeeR study. <i>Annals of Oncology</i> , 2020, 31, S1183.	0.6	11
31	Development and Validation of a Simplified Prognostic Score in SCLC. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100016.	0.6	6
32	Proposals for managing patients with thoracic malignancies during COVID-19 pandemic. <i>Respiratory Medicine and Research</i> , 2020, 78, 100769.	0.4	11
33	ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. <i>European Journal of Cardio-thoracic Surgery</i> , 2020, 58, 1-24.	0.6	50
34	ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. <i>European Respiratory Journal</i> , 2020, 55, 1900953.	3.1	151
35	First-Line Carboplatin Plus Pemetrexed with Pemetrexed Maintenance in HIV+ Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: The Phase II IFCT-1001 CHIVA Trial. <i>European Respiratory Journal</i> , 2020, 56, 1902066.	3.1	10
36	Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study. <i>Clinical Cancer Research</i> , 2019, 25, 6958-6966.	3.2	206

#	ARTICLE	IF	CITATIONS
37	Definition of Synchronous Oligometastatic Non-“Small Cell Lung Cancer” A Consensus Report. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2109-2119.	0.5	189
38	EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease. <i>European Journal of Cancer</i> , 2019, 122, 109-114.	1.3	33
39	Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial. <i>Clinical Cancer Research</i> , 2019, 25, 5759-5765.	3.2	13
40	A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 903-913.	0.5	132
41	Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort. <i>Clinical Lung Cancer</i> , 2019, 20, e564-e575.	1.1	49
42	Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2019, 14, 1095-1101.	0.5	159
43	MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial. <i>British Journal of Cancer</i> , 2019, 120, 387-397.	2.9	19
44	Targeted next-generation sequencing to assess tumor mutation burden: ready for prime-time in non-small cell lung cancer?. <i>Translational Lung Cancer Research</i> , 2019, 8, S323-S326.	1.3	6
45	Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?. <i>Translational Lung Cancer Research</i> , 2019, 8, S383-S386.	1.3	4
46	Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation. <i>Lung Cancer</i> , 2019, 127, 96-102.	0.9	31
47	Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 239-253.	5.1	342
48	Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 11-17.	1.1	6
49	Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-“small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, 201-207.	1.1	137
50	First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer. <i>Translational Cancer Research</i> , 2019, 8, 2514-2516.	0.4	3
51	Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey. <i>European Journal of Cancer</i> , 2018, 93, 37-46.	1.3	69
52	Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?. <i>European Respiratory Review</i> , 2018, 27, 170098.	3.0	21
53	The clinical utility of tumor mutational burden in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 639-646.	1.3	98
54	Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1762-1770.	0.5	60

#	ARTICLE	IF	CITATIONS
55	Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S1032-S1036.	0.6	16
56	Current and Former Smokers: Who Wants To Be Screened?. <i>Clinical Lung Cancer</i> , 2018, 19, 493-501.	1.1	13
57	Beliefs and behavior regarding e-cigarettes in a large cross-sectional survey. <i>Preventive Medicine Reports</i> , 2018, 10, 332-336.	0.8	4
58	Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study). <i>Oncotarget</i> , 2018, 9, 8253-8262.	0.8	25
59	Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. <i>British Journal of Cancer</i> , 2017, 116, 1505-1512.	2.9	25
60	Bevacizumab Plus Radiosurgery for Nonsquamous Non-Small Cell Lung Cancer Patients with Brain Metastases: Safe Combination?. <i>World Neurosurgery</i> , 2017, 107, 1047.e1-1047.e4.	0.7	8
61	Personalised medicine for nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2017, 26, 170066.	3.0	37
62	Adrenal surgery for oligometastatic tumors improves survival in selected cases. <i>Journal of Visceral Surgery</i> , 2017, 154, 87-91.	0.4	4
63	La survie de patients opérés de cancer oligométastatique. <i>Journal De Chirurgie Viscérale</i> , 2017, 154, 94-98.	0.0	0
64	Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 3591-3600.	0.8	121
65	Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 198-208.	1.4	46
66	Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. <i>Lancet</i> , 2016, 387, 1405-1414.	6.3	753
67	Necitumumab for non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1231-1239.	1.4	14
68	Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation. <i>European Journal of Cancer</i> , 2014, 50, 2771-2782.	1.3	11
69	Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma. <i>Cancer</i> , 2007, 110, 2248-2252.	2.0	65